Lazertinib Mesylate Hydrate
(la-ZER-tih-nib MEH-zih-layt HY-drayt)
Lazertinib works by blocking the activity of abnormal EGFR proteins that signal cancer cells to divide. This keeps cancer cells from growing and may kill them. Lazertinib can reach cancer cells in the brain, enabling it to treat cancers that have spread there. It is a type of targeted therapy drug called an EGFR tyrosine kinase inhibitor.
US Brand Name(s)
Lazcluze
FDA Approved
Yes
FDA label information for this drug is available at DailyMed.
Use in Cancer
Lazertinib mesylate hydrate is approved to treat adults with:
- non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery and has an abnormal EGFR gene. It is used with amivantamab as the first treatment.
More About Lazertinib Mesylate Hydrate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Lazertinib Mesylate Hydrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.